Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • USFDA issues warning...

    USFDA issues warning letter to Wockhardt's Ankleshwar plant

    Written by supriya kashyap kashyap Published On 2017-01-05T12:40:44+05:30  |  Updated On 5 Jan 2017 12:40 PM IST

    New Delhi : The US Food and Drug Administration (USFDA) has issued a warning letter to Wockhardt for violating current good manufacturing practice norms, including its failure to ensure proper clothing for workers at its Ankleshwar plant in Gujarat.


    In the letter to Wockhardt Chairman and Group CEO Habil Khorakiwala, the USFDA said inspectors during inspection from December 7 to 15, 2015, found "significant violations" of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals as well as for active pharmaceutical ingredients (API).


    USFDA has already banned import of products from the facility into the US market since August 5, 2016.


    Elaborating on the violations at the plant, USFDA noted that the company failed to ensure that manufacturing personnel wear clothing appropriate to protect drug product from contamination.


    "Our investigator observed employees working in gowns that had unravelled stitching extending from hoods, zippers, and pants. Your firm approved these gowns for operations. you should have discarded these garments," it noted.


    The other violations include the firm's failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile.


    "Under dynamic conditions, air did not sufficiently sweep across and away from sterile connections, so the sterility of any product processed under these conditions could be compromised," USFDA said.


    Besides, the inspectors identified multiple aseptic technique breaches during aseptic connection of the equipment.


    "Your equipment design and aseptic processing operator competencies appear to contribute to the lack of unidirectionality," the health regulator said.


    Also, the firm failed to ensure that laboratory records included complete data derived from all tests necessary to assure compliance with established specifications and standards, USFDA said.


    The firm also failed to exercise appropriate control over computer or related systems to assure that only authorised personnel institute changes in master production and control records.


    Commenting on the API production issues, USFDA said the company failed "to record activities at the time they are performed, and destruction of original records".

    Active Pharmaceutical IngredientAnkleshwar plantAPIHabil KhorakiwalaUS Food and Drug AdministrationUSFDAWockhardt
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok